Lung Therapeutics is a clinical-stage biopharmaceutical company developing novel peptide therapies targeting orphan pulmonary and fibrosis indications with few or no existing treatment options. The company's lead program is LTI-03, a peptide derived from the endogenous protein Cav1 designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in patients with idiopathic pulmonary fibrosis, with additional candidates targeting other fibrotic conditions. The company is pre-revenue and relies on third-party contract manufacturers for production; it intends to generate revenue through approved drug sales, milestone payments, and royalties from licensing partnerships once its candidates advance through clinical development and potential regulatory approval.